Tardive syndromes

Journal of the Neurological Sciences

Volumn 389, Issue , 2018, Pages 35-42

  Savitt, Daniel ^a   Jankovic, Joseph ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Dopamine receptor blocking agents; Dystonia; Neuroleptics; Stereotypy; Tardive dyskinesia; Tardive syndromes

Indexed keywords

AKATHISIA; CHOREA; DISEASE COURSE; DYSKINESIA; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; GAIT DISORDER; HUMAN; MYOCLONUS; OCULOGYRIC CRISIS; PARKINSONISM; PHENOMENOLOGY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SENSORY DYSFUNCTION; STEREOTYPY; TARDIVE DYSKINESIA; TARDIVE SENSORY SYNDROME; TARDIVE SYNDROME; TARDIVE TREMOR; TIC; TREMOR;

DOPAMINE RECEPTOR BLOCKING AGENT;

AKATHISIA, DRUG-INDUCED; DOPAMINE ANTAGONISTS; HUMANS; TARDIVE DYSKINESIA;

EID: 85042592680     PISSN: 0022510X     EISSN: 18785883     Source Type: Journal    
DOI: 10.1016/j.jns.2018.02.005     Document Type: Review

References (107)

1. Frei, K., Truong, D., Fahn, S., Jankovic, J., Hauser, Robert A., The nosology of tardive syndromes. J. Neurol. Sci., 2018, 10.1016/j.jns.2018.02.008 [In this issue].
2. Faurbye, A., Rasch, P.J., Petersen, P.B., Brandborg, G., Pakkenberg, H., Neurological symptoms in pharmacotherapy of psychoses. Acta Psychiatr. Scand. 40 (1964), 10–27.
3. Morrens, M., Hulstijn, W., Lewi, P.J., De Hert, M., Sabbe, B.G.C., Stereotypy in schizophrenia. Schizophr. Res. 84 (2006), 397–404.
4. Fahn, S., Jankovic, J., Hallett, M., Principles and Practice of Movement Disorders. 2nd ed., 2011 (380-8 pp.).
5. Wijemanne, S., Jankovic, J., Movement disorders in catatonia. J. Neurol. Neurosurg. Psychiatry 86 (2015), 825–832.
6. American Psychiatric Association, Medication-induced movement disorders and other adverse effects of medication. Diagnostic and Statistical Manual of Mental Disorders, fifth edition, 2013, American Psychiatric Association.
7. Fahn, S., Jankovic, J., Hallett, M., Principles and Practice of Movement Disorders. 2nd ed., 2011, 415–446.
8. Barow, E., Schneider, S.A., Bhatia, K.P., Ganos, C., Oculogyric crises: etiology, pathophysiology and therapeutic approaches. Parkinsonism Relat. Disord. 36 (2017), 3–9.
9. Burkhard, P.R., Acute and subacute drug-induced movement disorders. Parkinsonism Relat. Disord. 20:Suppl. 1 (2014), S108–12.
10. Lohr, J.B., Eidt, C.A., Abdulrazzaq Alfaraj, A., Soliman, M.A., The clinical challenges of akathisia. CNS Spectr. 20:Suppl. 1 (2015), 1–14.
11. Waln, O., Jankovic, J., An update on tardive dyskinesia: from phenomenology to treatment. Tremor Other Hyperkinet Mov. 3 (2013), 1–11.
12. Vijayakumar, D., Jankovic, J., Drug-induced dyskinesia, part 2: treatment of tardive dyskinesia. Drugs 76 (2016), 779–787.
13. Raharaj, S.K., Kongasseri, S., Behere, R.V., Sharma, P.S., Mirtazapine for antipsychotic-induced acute akathisia: a systematic review and meta-analysis of randomized placebo-controlled trials. Ther. Adv. Psychopharmacol. 5 (2015), 307–313.
14. Velamoor, R., Neuroleptic malignant syndrome: a neuro-psychiatric emergency: recognition, prevention, and management. Asian J. Psychiatr. 29 (2017), 106–109.
15. Ware, M.R., Feller, D.B., Hall, K.L., Neuroleptic malignant syndrome: diagnosis and management. Prim Care Companion CNS Disord., 20(1), 2018.
16. Strassnig, M., Rosenfeld, A., Harvey, P.D., Tardive Dyskinesia: Motor System Impairments, Cognition and Everyday Functioning. 2017, 1–8.
17. Mailman, R.B., Murthy, V., Third generation antipsychotic drugs: partial agonism or receptor functional selectivity?. Curr. Pharm. Des. 16 (2010), 488–501.
18. Frankel, J.S., Schwartz, T.L., Brexpiprazole and cariprazine: distinguishing two new atypical antipsychotics from the original dopamine stabilizer aripiprazole. Ther. Adv. Psychopharmacol. 7 (2017), 29–41.
19. Farah, A., Atypicality of atypical antipsychotics. Prim Care Companion J. Clin. Psychiatry 7 (2005), 268–274.
20. Wijemanne, S., Jankovic, J., Evans, R.W., Movement disorders from the use of metoclopramide and other antiemetics in the treatment of migraine. Headache 56 (2016), 153–161.
21. Kenney, C., Hunter, C., Davidson, A., Jankovic, J., Metoclopramide, an increasingly recognized cause of tardive dyskinesia. J. Clin. Pharmacol. 48 (2008), 379–384.
22. Pasricha, P.J., Pehlivanov, N., Sugumar, A., Jankovic, J., Drug insight: from disturbed motility to disordered movement—a review of the clinical benefits and medicolegal risks of metoclopramide. Nat. Clin. Pract. Gastroenterol. Hepatol. 3 (2006), 138–148.
23. Jankovic, J., Dopamine depleters in the treatment of hyperkinetic movement disorders. Expert. Opin. Pharmacother. 17 (2016), 2461–2470.
24. Cornett, E.M., Novitch, M., Kaye, A.D., Kata, V., Kaye, A.M., Medication-induced tardive dyskinesia: a review and update., 17, 2017, 162–174.
25. Lerner, P.P., Miodownik, C., Lerner, V., Tardive dyskinesia (syndrome): current concept and modern approaches to its management. Psychiatry Clin. Neurosci. 69 (2015), 321–334.
26. Lehman, A.F., Lieberman, J.A., Dixon, L.B., McGlashan, T.H., Miller, A.L., Perkins, D.O. et al., American psychiatric association, steering committee on practice guidelines, practice guideline for the treatment of patients with schizophrenia, second edition. Am. J. Psychiatry 161 (2004), 1–56.
27. Kim, J., MacMaster, E., Schwartz, T.L., Tardive dyskinesia in patients treated with atypical antipsychotics: case series and brief review of etiologic and treatment considerations. Drugs Context 3 (2014), 1–10.
28. Carbon, M., Hsieh, C.H., Kane, J.M., Correll, C.U., Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis. J. Clin. Psychiatry 78 (2017), e264–e278.
29. Peña, M.S., Yaltho, T.C., Jankovic, J., Tardive dyskinesia and other movement disorders secondary to aripiprazole. Mov. Disord. 26 (2011), 147–152.
30. Goyal, R., Devi, S.H., A case of aripiprazole induced tardive dyskinesia in a neuroleptic-naïve patient with two years of follow up. Clin. Psychopharmacol. Neurosci. 12 (2014), 69–71.
31. Patra, S., Tardive dyskinesia and covert dyskinesia with aripiprazole: a case series., 11, 2016, 102–103.
32. Heitzmann, E., Javelot, H., Weiner, L., Michel, B., C. Description, Case Report A Case of Aripiprazole-induced Tardive Dyskinesia With Dramatic Evolution. 2016.
33. Bhidayasiri, R., Boonyawairoj, S., Spectrum of tardive syndromes: clinical recognition and management. Postgrad. Med. J. 87 (2011), 132–141.
34. Vinuela, A., Kang, U.J., Reversibility of tardive dyskinesia syndrome. Tremor Other Hyperkinet Mov., 4, 2014, 282.
35. Zutshi, D., Cloud, L.J., Factor, S.A., Tardive syndromes are rarely reversible after discontinuing dopamine receptor blocking agents: experience from a university-based movement disorder clinic. Tremor Other Hyperkinetic Mov. 4 (2014), 1–9.
36. Kiriakakis, V., Bhatia, K.P., Quinn, N.P., Marsden, C.D., The natural history of tardive dystonia. A long-term follow-up study of 107 cases. Brain 121 (1998), 2053–2066.
37. Glazer, W.M., Morgenstern, H., Schooler, N., Berkman, C.S., Moore, D.C., Predictors of improvement in tardive dyskinesia following discontinuation of neuroleptic medication. Br. J. Psychiatry 157 (1990), 585–592.
38. Teo, J.T., Edwards, M.J., Bhatia, K., Tardive dyskinesia is caused by maladaptive synaptic plasticity: a hypothesis. Mov. Disord. 27 (2012), 1205–1215.
39. Schooler, N.R., Kane, J.M., Research diagnoses for tardive dyskinesia. Arch. Gen. Psychiatry 39 (1982), 486–487.
40. Gardos, G., Cole, J.O., Tarsy, D., Withdrawal syndromes associated with antipsychotic drugs. Am. J. Psychiatry 135 (1978), 1321–1324.
41. A.P.A., Practice guideline for the treatment of patients with bipolar disorder. Am. J. Psychiatry 151 (1994), 1–36.
42. Bark, N., Florida, D., Gera, N., Varardi, R., Harghel, L., Adlington, K., Evaluation of the routine clinical use of the brief psychiatric rating scale (BPRS) and the abnormal involuntary movement scale (AIMS). J. Psychiatr. Pract. 17 (2011), 300–303.
43. Guy, W., ECDEU Assessment Manual for Psychopharmacology: Revised. 1976, 534–537.
44. Fahn, S., Neural mechanisms in disorders of movement. Crossman, A., Sambrook, M.A., (eds.) Neural Mechanism in Disorders of Movement, 1989 (249–267 pp.).
45. Stacy, M., Cardoso, F., Jankovic, J., Tardive stereotypy and other movement disorders in tardive dyskinesias. Neurology 43 (1993), 937–941.
46. Blanchet, P.J., Popovici, R., Guitard, F., Rompré P.H., Lamarche, C., Lavigne, G.J., Pain and denture condition in edentulous orodyskinesia: comparisons with tardive dyskinesia and control subjects. Mov. Disord. 23 (2008), 1837–1842.
47. Jung, H.H., Danek, A., Walker, R.H., Neuroacanthocytosis syndromes. Orphanet J. Rare Dis., 6, 2011, 68.
48. Jankovic, J., Tardive syndromes and other drug-induced movement disorders. Clin. Neuropharmacol. 18 (1995), 197–214.
49. Fekete, R., Jankovic, J., Upper facial chorea in Huntington disease. J. Clin. Mov. Disord., 1, 2014, 7.
50. Lumetti, S., Ghiacci, G., Macaluso, G.M., Amore, M., Galli, C., Calciolari, E. et al., Tardive dyskinesia, oral parafunction, and implant-supported rehabilitation. Case Rep. Dent., 2016 (Epub 2016 Dec 6).
51. Kaneko, K., Yuasa, T., Miyatake, T., Tsuji, S., Stereotyped hand clasping: an unusual tardive movement disorder. Mov. Disord. 8 (1993), 230–231.
52. Yassa, R., Lal, S., Respiratory irregularity and tardive dyskinesia. A prevalence study. Acta Psychiatr. Scand. 73 (1986), 506–510.
53. Wilcox, P.G., Bassett, A., Jones, B., Fleetham, J.A., Respiratory dysrhythmias in patients with tardive dyskinesia. Chest 105 (1994), 203–207.
54. Horiguchi, J., Shingu, T., Hayashi, T., Kagaya, A., Yamawaki, S., Horikawa, Y., Kitadai, Y., Inoue, M., Nishikawa, T., Antipsychotic-induced life-threatening “esophageal dyskinesia”. Int. Clin. Psychopharmacol. 14 (1999), 123–127.
55. Ure, R.J., Dhanju, S., Lang, A.E., Fasano, A., Unusual tremor syndromes: know in order to recognise. J. Neurol. Neurosurg. Psychiatry 87 (2016), 1191–1203.
56. Liang, C.S., Yang, F.W., Huang, Y.C., Rabbit syndrome following discontinuation of paliperidone in a patient with schizoaffective disorder. J. Clin. Psychopharmacol. 32 (2012), 720–721.
57. Sansare, K., Singh, D., Khanna, V., Karjodkar, F.R., Risperidone-induced rabbit syndrome: an unusual movement disorder. N. Y. State Dent. J. 78 (2012), 44–46 (78).
58. Druckman, R., Seelinger, D., Thulin, B., Chronic involuntary movements induced by phenothiazines. J. Nerv. Ment. Dis. 135 (1962), 69–76.
59. Burke, R.E., Fahn, S., Jankovic, J., Marsden, C.D., Lang, A.E., Gollomp, S. et al., Tardive dystonia: late-onset and persistent dystonia caused by antipsychotic drugs. Neurology 32 (1982), 1335–1346.
60. Kang, U.J., Burke, R.E., Fahn, S., Natural history and treatment of tardive dystonia. Mov. Disord. 1 (1986), 193–208.
61. Wojcik, J.D., Falk, W.E., Fink, J.S., Cole, J.O., Gelenberg, A.J., A review of 32 cases of tardive dystonia. Am. J. Psychiatry 148 (1991), 1055–1059.
62. van Harten, P.N., Matroos, G.E., Van Os, J., The course of tardive dystonia in Afro Caribbean patients, a population-based study: the Curacao extrapyramidal syndromes study: VII. Schizophr. Res. 98 (2008), 79–83.
63. Konrad, C., Vollmer-Haase, J., Gaubitz, M., Nabavi, D.G., Reilmann, R., Knecht, S., Fracture of the odontoid process complicating tardive dystonia. Mov. Disord. 19 (2004), 983–985.
64. Tan, E.K., Jankovic, J., Tardive and idiopathic oromandibular dystonia: a clinical comparison. J. Neurol. Neurosurg. Psychiatry 68 (2000), 186–190.
65. Samie, M.R., Dannenhoffer, M.A., Rozek, S., Life-threatening tardive dyskinesia caused by metoclopramide. Mov. Disord. 2 (1987), 125–129.
66. Hayashi, T., Nishikawa, T., Koga, I., Uchida, Y., Yamawaki, S., Life-threatening dysphagia following prolonged neuroleptic therapy. Clin. Neuropharmacol. 20 (1997), 77–81.
67. van Harten, P.N., Hoek, H.W., Matroos, G.E., Koeter, M., Kahn, R.S., The inter-relationships of tardive dyskinesia, parkinsonism, akathisia and tardive dystonia: the Curaçao extrapyramidal syndromes study II. Schizophr. Res. 26 (1997), 235–242.
68. Gardos, G., Cole, J.O., Salomon, M., Schniebolk, S., Clinical forms of severe tardive dyskinesia. Am. J. Psychiatry 144 (1987), 895–902.
69. Fountoulakis, K.N., Samara, M., Siapera, M., Iacovides, A., Tardive Tourette-like syndrome. Int. Clin. Psychopharmacol. 26 (2011), 237–242.
70. Braude, W.M., Barnes, T.R., Late-onset akathisia-an indicant of covert dyskinesia: two case reports. Am. J. Psychiatry 140 (1983), 611–612.
71. Fahn, S., Tardive dyskinesia may be only akathisia. N. Engl. J. Med. 299 (1978), 202–203.
72. Weiner, W.J., Luby, E.D., Persistent akathisia following neuroleptic withdrawal. Ann. Neurol. 13 (1983), 466–467.
73. Munetz, M.R., Cornes, C.L., Akathisia, pseudoakathisia and tardive dyskinesia: clinical examples. Compr. Psychiatry 23 (1982), 345–352.
74. Burke, R.E., Kang, U.J., Jankovic, J., Miller, L.G., Fahn, S., Tardive akathisia: an analysis of clinical features and response to open therapeutic trials. Mov. Disord. 4 (1989), 157–175.
75. Barnes, T.R., Braude, W.M., Akathisia variants and tardive dyskinesia. Arch. Gen. Psychiatry 42 (1985), 874–878.
76. Aquino, C.C.H., Lang, A.E., Tardive dyskinesia syndromes: current concepts. Parkinsonism Relat. Disord. 20 (2014), S113–S117.
77. Jankovic, J., Leg stereotypy disorder. J. Neurol. Neurosurg. Psychiatry 87:2 (2016 Feb), 220–221.
78. Lotia, M., York, M.K., Strutt, A.M., Jankovic, J., Leg stereotypy syndrome: phenomenology and prevalence. J. Neurol. Neurosurg. Psychiatry, 2018 (in press, epub ahead of print).
79. Little, J.T., Jankovic, J., Tardive myoclonus. Mov. Disord. 2 (1987), 307–311.
80. Tominaga, H., Fukuzako, H., Izumi, K., Koja, T., Fukuda, T., Fujii, H., Matsumoto, K., Sonoda, H., Imamura, K., Tardive myoclonus. Lancet, 329, 1987, 322.
81. Fukuzako, H., Tominaga, H., Izumi, K., Koja, T., Nomoto, M., Hokazono, Y., Kamei, K., Fujii, H., Fukuda, T., Matsumoto, K., Postural myoclonus associated with long-term administration of neuroleptics in schizophrenic patients. Biol. Psychiatry 27 (1990), 1116–1126.
82. Stacy, M., Jankovic, J., Tardive tremor. Mov. Disord. 7 (1992), 53–57.
83. Tarsy, D., Indorf, G., Tardive tremor due to metoclopramide. Mov. Disord. 17 (2002), 620–621.
84. Shprecher, D., Sensory trick with metoclopramide-associated tardive tremor. BMJ Case Rep., 2012, 2012 (bcr1120115156-bcr1120115156).
85. Patel, N., Hanfelt, J., Marsh, L., Jankovic, J., Alleviating manoeuvres (sensory tricks) in cervical dystonia. J. Neurol. Neurosurg. Psychiatry 85 (2014), 882–884.
86. Yogaratnam, J., Xu, C., Thinn, D.S.S., Yoong, L.K., Khoo, C.L., Sim, K., De novo tardive Tourette-like syndrome after prolonged combination depot and oral neuroleptic therapy. Acta Neuropsychiatr. 25 (2013), 122–124.
87. Black, K.J., Jankovic, J., Hershey, T., McNaught, K.S.P., Mink, J.W., Walkup, J., Progress in research on Tourette syndrome. J. Obsessive Compuls. Relat. Disord. 3 (2014), 359–362.
88. Cardoso, F., Differential diagnosis of Huntington's disease: what the clinician should know. Neurodegener. Dis. Manag. 4 (2014), 67–72.
89. Jankovic, J., Glass, J.P., Metoclopramide-induced phantom dyskinesia. Neurology 35 (1985), 432–435.
90. Simpson, G.M., Shrivastava, R.K., Abnormal gaits in tardive dyskinesia. Am. J. Psychiatry, 135, 1978, 865.
91. Yassa, R., Functional impairment in tardive dyskinesia: medical and psychosocial dimensions. Acta Psychiatr. Scand. 80 (1989), 64–67.
92. Lauterbach, E.C., Singh, H., Simpson, G.M., Morrison, R.L., Gait disorders in tardive dyskinesia. Acta Psychiatr. Scand., 82, 1990, 267.
93. Kuo, S.H., Jankovic, J., Tardive gait. Clin. Neurol. Neurosurg. 110 (2008), 198–201.
94. Bower, J.H., Dickson, D.W., Taylor, L., Maraganore, D.M., Rocca, W.A., Clinical correlates of the pathology underlying parkinsonism: a population perspective. Mov. Disord. 17 (2002), 910–916.
95. Loberboym, M., Traves, T.A., Melamed, E., Lampl, Y., Hellman, M., Djaldetti, R., [123 I]-EP/CIT SPECT imaging for distinguishing drug-induced Parkinsonism from Parkinson's disease. Mov. Disord. 21 (2006), 510–514.
96. Seeman, P., Tinazzi, M., Loss of dopamine neuron terminals in antipsychotic-treated schizophrenia; relation to tardive dyskinesia., 44, Jul 2013, 178–183.
97. Won, M.S., Mikos, A., Hurd, M., Fernandez, H., Eskin, T., Romrell, J., Okun, M.S., Tardive parkinsonism in a bipolar patient: post-mortem examination supports a physiological rather than pathological dysfunction. Neurocase 15 (2008), 66–69.
98. Chung, S.J., Yoo, H.S., Moon, H., Oh, J.S., Kim, J.S., Park, Y.H. et al., Early-onset drug-induced parkinsonism after exposure to offenders implies nigrostriatal dopaminergic dysfunction. J. Neurol. Neurosurg. Psychiatry 89 (2017), 169–174.
99. Shuaib, U.A., Rajput, A.H., Robinson, C.A., Rajput, A., Neuroleptic-induced Parkinsonism: clinicopathological study. Mov. Disord. 31 (2016), 360–365.
100. Polizos, P., Engelhardt, D.M., Hoffman, S.P., Waizer, J., Neurological consequences of psychotropic drug withdrawal in schizophrenic children. J. Autism Child. Schizophr. 3 (1973), 247–253.
101. Mejia, N.I., Jankovic, J., Tardive dyskinesia and withdrawal emergent syndrome in children. Expert. Rev. Neurother. 10 (2010), 893–901.
102. Fahn, S., The tardive dyskinesias. Matthews, W.B., Glaser, G.H., (eds.) Recent Advances in Clinical Neurology, 4th ed., 1984 (229–260 pp.).
103. Wijemanne, S., Jankovic, J., Dopa-responsive dystonia-clinical and genetic heterogeneity. Nat. Rev. Neurol. 11 (2015), 414–424.
104. Slow, E.J., Lang, A.E., Oculogyric crises: a review of phenomenology, etiology, pathogenesis, and treatment. Mov. Disord. 32 (2017), 193–202.
105. Fitzgerald, P.M., Jankovic, J., Tardive oculogyric crises. Neurology 39 (1989), 1434–1437.
106. Patel, N., Jankovic, J., Hallett, M., Sensory aspects of movement disorders. Lancet Neurol. 13 (2014), 100–112.
107. Ford, B., Greene, P., Fahn, S., Oral and genital tardive pain syndromes. Neurology 44 (1994), 2115–2119.